Validated biomarkers: The key to precision treatment in patients with breast cancer.

摘要: Recent DNA sequencing and gene expression studies have shown that at a molecular level, almost every case of breast cancer is unique different from other cancers. For optimum management therefore, patient should receive treatment guided by the composition their tumor, i.e., precision treatment. While such scenario still some distance into future, biomarkers are beginning to play an important role in preparing way for In particular, increasingly being used predicting outcome informing as most appropriate type systemic therapy be administered. Mandatory newly diagnosed estrogen receptors progesterone selecting patients endocrine HER2 identifying likely benefit anti-HER2 therapy. Amongst best validated prognostic biomarker tests uPA/PAI-1, MammaPrint Oncotype DX. Although currently, there no available response specific forms chemotherapy, uPA/PAI-1 DX can aid identification lymph node-negative adjuvant general. order accelerate progress towards women with cancer, we need additional predictive biomarkers, especially enhancing positive value therapies, well chemotherapy. The ultimate test achieving goal will require combination transcriptomic analysis patient's tumor.